Expanding the Phenotype of Molybdenum Cofactor Deficiency in Neonates: Report of Two Cases

Abstract

Molybdenum cofactor deficiency (MoCD) is a rare neurometabolic disorder characterized by intractable seizures, progressive microcephaly, tone abnormalities, facial dysmorphism, and feeding difficulties in the neonatal period. We present two different neonatal cases of MoCD with atypical presentations which could have been easily missed. One is a preterm baby admitted with features of sepsis, poor perfusion, and seizures who later developed tone abnormalities and feeding difficulty. The second is a term baby who presented with stridor, respiratory distress, and metabolic acidosis followed by intractable seizures and encephalopathy. Both babies had characteristic radiological and biochemical findings, and genome sequencing identified mutations in MOCS2 and MOCS1 genes, respectively. MoCD presenting as hypoxic-ischemic encephalopathy and cerebral palsy are well described, but its presentation in preterm with “sepsis-like features with drug-responsive seizures” in the early newborn period is not described, and can also cause unnecessary delay in the diagnosis. Its clinical presentation with “stridor, respiratory distress, and metabolic acidosis” is also described for the first time in literature.

Keywords

neonate - seizure - molybdenum cofactor deficiency - neurometabolic disorder

Authors' Contributions

S.C., N.P., D.M., and M.K. were involved in the clinical management of the patient. S.C. supported in data collection and drafting initial manuscript. M.K. gave critical inputs and supervised the draft. N.P. and D.M. provided critical inputs and edited the manuscript. The manuscript was approved by all the authors.

Publication History

Received: 15 April 2021

Accepted: 09 July 2021

Article published online:
11 August 2021

• References

• 1 Arnold GL, Greene CL, Stout JP, Goodman SI. Molybdenum cofactor deficiency. J Pediatr 1993; 123 (04) 595-598
• 2 Topcu M, Coskun T, Haliloglu G, Saatci I. Molybdenum cofactor deficiency: report of three cases presenting as hypoxic-ischemic encephalopathy. J Child Neurol 2001; 16 (04) 264-270
• 3 Teksam O, Yurdakok M, Coskun T. Molybdenum cofactor deficiency presenting with severe metabolic acidosis and intracranial hemorrhage. J Child Neurol 2005; 20 (02) 155-157
• 4 Kavukçu S, Soylu A, Sahin B, Türkmen M, Aydin A, Dirik E. Clinical quiz. Molybdenum cofactor deficiency. Pediatr Nephrol 2000; 14 (12) 1145-1147
• 5 Mechler K, Mountford WK, Hoffmann GF, Ries M. Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. Genet Med 2015; 17 (12) 965-970
• 6 Johnson JL, Duran M. Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The Metabolic and Molecular Basis of Inherited Disease. 8th edition. New York: McGraw Hill; 2001: 3163-3177
• 7 Duran M, Beemer FA, van de Heiden C. et al. Combined deficiency of xanthine oxidase and sulphite oxidase: a defect of molybdenum metabolism or transport?. J Inherit Metab Dis 1978; 1 (04) 175-178
• 8 Johnson JL, Waud WR, Rajagopalan KV, Duran M, Beemer FA, Wadman SK. Inborn errors of molybdenum metabolism: combined deficiencies of sulfite oxidase and xanthine dehydrogenase in a patient lacking the molybdenum cofactor. Proc Natl Acad Sci U S A 1980; 77 (06) 3715-3719
• 9 Reiss J, Johnson JL. Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH. Hum Mutat 2003; 21 (06) 569-576
• 10 Bayram E, Topcu Y, Karakaya P. et al. Molybdenum cofactor deficiency: review of 12 cases (MoCD and review). Eur J Paediatr Neurol 2013; 17 (01) 1-6
• 11 Scelsa B, Gasperini S, Righini A, Iascone M, Brazzoduro VG, Veggiotti P. Mild phenotype in Molybdenum cofactor deficiency: a new patient and review of the literature. Mol Genet Genomic Med 2019; 7 (06) e657
• 12 Misko AL, Liang Y, Kohl JB, Eichler F. Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency. Neurol Genet 2020; 6 (04) e486
• 13 Macaya A, Brunso L, Fernández-Castillo N. et al. Molybdenum cofactor deficiency presenting as neonatal hyperekplexia: a clinical, biochemical and genetic study. Neuropediatrics 2005; 36 (06) 389-394
• 14 Vijayakumar K, Gunny R, Grunewald S. et al. Clinical neuroimaging features and outcome in molybdenum cofactor deficiency. Pediatr Neurol 2011; 45 (04) 246-252
• 15 Zaki MS, Selim L, El-Bassyouni HT. et al. Molybdenum cofactor and isolated sulphite oxidase deficiencies: Clinical and molecular spectrum among Egyptian patients. Eur J Paediatr Neurol 2016; 20 (05) 714-722
• 16 Veldman A, Santamaria-Araujo JA, Sollazzo S. et al. Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics 2010; 125 (05) e1249-e1254
• 17 Schwahn BC, Van Spronsen FJ, Belaidi AA. et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet 2015; 386 (10007): 1955-1963